RxSIGHT

Investor Presentation

July 2026

Disclaimer & Forward-looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “ projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of the RxSight, Inc. (“RxSight,” “we” or “us”) management as well as assumptions made by and information currently available to RxSight. Such statements reflect the current views of RxSight with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about RxSight. Such statements may include, without limitation, statements regarding: (i) our preliminary second quarter 2026 financial and operating results and the anticipated timing of announcing unaudited second quarter 2026 financial results; (ii) our product development pipeline and anticipated timelines; (iii) potential payments that we may receive in connection with the Alcon Collaboration Agreement, a description of which (including material terms and conditions) may be found in the Current Report on Form 8-K filed on July 6, 2026, with the Securities and Exchange Commission (SEC), including potential milestone payments and royalties; (v) RxSight’s and Alcon’s respective rights and obligations under the Alcon Collaboration Agreement; (vi) our belief that IOL adjustability is becoming a foundation of premium outcomes, drives superior practice economics, and wins long-term; and (vii) our growth strategy, including, without limitation, with respect to international expansion.

These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including, without limitation, those related to the Alcon RxSight Collaboration (uncertainty as to whether the anticipated benefits and opportunities of the proposed collaboration may be realized or make take longer to realize or may cost more than expected; unexpected hurdles, costs or delays; challenges in technology transfer and manufacturing; challenges inherent in new product candidate development, including obtaining regulatory approvals; challenges associated with collaborating with third parties, including intellectual property, operational, financial and other risks; uncertainty of commercial success for new products; and the ability of RxSight and Alcon to successfully execute their respective strategic plans) and those that may be found in our prior press releases and SEC filings, including those under the heading “Risk Factors” in Part II, Item 1A of RxSight’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on May 6, 2026, as well as in our subsequent filings with the SEC, which are available on the SEC’s website at www.sec.gov. We caution you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. We do not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.

This presentation contains estimates, projections and other information concerning our business, our industry and the markets for our products, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this presentation from our internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar methodologies is subject to risks, uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.

OUR VISION

Transform cataract surgery outcomes via the power of **adjustability**

Adjustability is Becoming a Foundation of Premium Outcomes

Adjustability Offers:

- Targeted refractive accuracy
- Customization to patient lifestyle
- High patient satisfaction and confidence

The Ability to Adjust the Lens After Surgery Delivers Unmatched Refractive Precision



Other Lenses

LAL eyes have

14.5 X

better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl ≤ 0.50 D)[1]



LAL

1. Data on file - RxSight Post-Approval Study

Developing First and Only Suite of Adjustable IOLs

Improved Workflow with Fewer Required Visits

Expanded Patient Choice

Leverages Adjustability Infrastructure

Next Generation LAL

Best-in-class visual quality and optical clarity with postoperative refractive optimization to consistently achieve targeted visual outcomes

LAL Toric

Built-in toric correction with postoperative refinement of residual sphere and cylinder to maximize visual acuity

Next Generation LAL +

Improved intermediate vision for everyday activities while preserving high-quality optical performance, with adjustability enabling precise refractive targeting

Alcon Collaboration Products

Alcon simultaneous vision intraocular lenses (“SVIOLs”) combined with RxSight's light-adjustable technology, enabling surgeons to fine-tune visual outcomes after surgery

Product candidates described above and related timelines are subject to regulatory approvals

RxSight Alcon Collaboration

Partnership Scope and Key Terms	Scope	**Collaboration Products**	Simultaneous Vision Intraocular Lenses (“SVIOLs”)
		License	Non-Exclusive
		Term	10 years from first commercial sale; autorenewal for additional 5-year terms
	Economic Terms	**Upfront** [1]	$ 60m
		Additional Milestones [1]	$ 140m
		Total Upfront + Milestones [1]	**$ 200m**
		Royalties [1]	30% of net sales, subject to minimum annual royalties and customary adjustments

1. All payments are subject to the terms and conditions of the Collaboration Agreement. A description of RxSight’s and Alcon’s respective rights and obligations under the Collaboration Agreement (including material terms and conditions) may be found in the Current Report on Form 8-K filed on July 6, 2026, with the Securities and Exchange Commission (SEC)

Growing Data Set and Clinical Consensus

Real world data from over 7,000 eyes

ACCURACY

>94%

+/- MRSE [1]

BINOCULAR OUTCOMES

>90%

20/25 distance and J2 near without glasses [1]

LAL Customer Survey

90%

believe LAL provides highest quality of vision [2]

79%

would select for their own premium IOL surgery (vs 11% for multifocal and 7% EDOF) [2]

1. RxSight Data on File: PMCS-002
2. 2025 RxSight Customer Survey

Boosting profitability through premium IOL adoption

Adjustability Drives Superior Practice Economics

Expand the Premium Market

Data shows 40% of LAL patients would have otherwise chosen a standard, non-premium lens.[1]

Command a Premium Price

Patients demonstrate a high willingness to pay for customized quality, supporting a significant price premium over fixed alternatives.

Unify the Care Team

Enables both surgeons and optometrists to actively participate in and benefit from the premium IOL segment.

$2,064[1]

Average additional practice net revenue per LAL implanted

1. Haffey & Company 2024 Economic Study of LAL Users

Scaling Adjustability Worldwide

MARKETS

10 approved markets

across three global regions

NORTH AMERICA

- United States
- Mexico
- Canada

EUROPE

- United Kingdom
- European Union

ASIA-PACIFIC

- South Korea
- Australia
- Singapore
- New Zealand
- Hong Kong[1]

STRATEGY

Focus on Top Premium Markets

Prioritizing entry into the largest of the world's top-20 premium IOL markets.

Lean, Scalable Go-to-Market

Direct model in high-volume markets; hub-and-spoke and distributor-hybrid models elsewhere.

Early Adopters & KOL Development

Win early-adopters and KOLs to build clinical evidence and peer referrals.

1. Hong Kong: U.S. FDA approval qualifies as a recognized reference-market clearance under the Medical Device Administrative Control System (MDACS).
2. Market Scope 2025 Premium Cataract Surgery Market Report, October 2025

Historical Trends

A well-established commercial platform validated by a large installed base

LAL Units



LDD Installed Base



Total Revenue (in millions)



Preliminary Second Quarter 2026 Results[1]

$32M-$34M

Total Company Revenue[2]

24,917

LALs Sold

1,166

LDD Installed Base[3]

$209M

Cash, Cash Equivalents & ST Investments

1. Financial and operating results are preliminary estimates. Actual results remain subject to completion of financial statements and review by RxSight's independent registered public accounting firm
2. Including between $5-7 million recognized from Alcon collaboration agreement, with the specific amount to be reported with full financial results in August
3. Inclusive of 11 LDDs sold and 1 LDD rental unit placed in Q2

Adjustability Wins Long-Term

RxSight offers the only Adjustable IOL Platform

- **Differentiated Platform**
- **Expanding Pipeline**
- **Global Expansion**
- **Strong Balance Sheet**

RxSIGHT

Thank You